Ramin Alemzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ramin Alemzadeh has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
David T. Wyatt
From the Department of Pediatrics, Medical College of Wisconsin, Children's Research Institute, Milwaukee, Wisconsin
2 shared publicationsElaine A. Parton
Medical College of Wisconsin
2 shared publicationsElaine Parton
Department of Pediatrics, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
2 shared publicationsHanaa Zidan
Section of Pediatric Endocrinology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, Michigan
2 shared publicationsJ. Kichler
Department of Pediatrics, Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, Wisconsin
2 shared publicationsJessica Kichler
2 shared publications
Latest Publications
- Open Access
- 17 February 2011
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (3) , 681-685
Impaired Endothelial Function in Preadolescent Children With Type 1 Diabetes
OBJECTIVE: We evaluated the prevalence of endothelial dysfunction as measured by flow-mediated dilatation (FMD) of the brachial artery and carotid intima-media thickness (c-IMT) in relationship to vascular inflammatory biomarkers in preadolescent children with type 1 diabetes. RESEARCH DESIGN AND METHODS: We studied 21 type 1 diabetic children (aged 8.3 ± 0.3 years with diabetes duration of 4.3 ± 0.4 years) and 15 group-matched healthy siblings (aged 7.6 ± 0.3 years). Fasting plasma glucose (FPG), lipid profile, HbA1c, high-sensitivity C-reactive protein (hs-CRP), fibrinogen, homocysteine, and erythrocyte (red blood cell [RBC]) folate were evaluated in all subjects. Each subject underwent c-IMT and brachial artery FMD percentage (FMD%) measurements using high-resolution vascular ultrasound. RESULTS: Type 1 diabetic children had higher FPG (173.4 ± 7.9 mg/dL vs. 81.40 ± 1.7 mg/dL; P < 0.0001), HbA1c (8.0 ± 0.2% vs. 5.0 ± 0.1%; P < 0.0001), and hs-CRP (1.8 ± 0.3 vs. 0.70 ± 0.2; P = 0.017) than control children without significant differences in BMI, homocysteine, and fibrinogen levels; RBC folate content; and c-IMT between the groups. Children with type 1 diabetes had lower FMD% than control children (7.1 ± 0.8% vs. 9.8 ± 1.1%; P = 0.04), whereas c-IMT did not differ between groups. CONCLUSIONS: Preadolescent children with type 1 diabetes and mean diabetes duration of 4 years displayed evidence of low-intensity vascular inflammation and attenuated FMD measurements. These data suggest that endothelial dysfunction and systemic inflammation, known harbingers of future cardiovascular risk, are present even in preadolescent children.
- 17 February 2011
- Published by American Diabetes Association in Diabetes Care
- Vol. 34 (3) , 681-685
Open AccessImpaired Endothelial Function in Preadolescent Children With Type 1 Diabetes
OBJECTIVE: We evaluated the prevalence of endothelial dysfunction as measured by flow-mediated dilatation (FMD) of the brachial artery and carotid intima-media thickness (c-IMT) in relationship to vascular inflammatory biomarkers in preadolescent children with type 1 diabetes. RESEARCH DESIGN AND METHODS: We studied 21 type 1 diabetic children (aged 8.3 ± 0.3 years with diabetes duration of 4.3 ± 0.4 years) and 15 group-matched healthy siblings (aged 7.6 ± 0.3 years). Fasting plasma glucose (FPG), lipid profile, HbA1c, high-sensitivity C-reactive protein (hs-CRP), fibrinogen, homocysteine, and erythrocyte (red blood cell [RBC]) folate were evaluated in all subjects. Each subject underwent c-IMT and brachial artery FMD percentage (FMD%) measurements using high-resolution vascular ultrasound. RESULTS: Type 1 diabetic children had higher FPG (173.4 ± 7.9 mg/dL vs. 81.40 ± 1.7 mg/dL; P < 0.0001), HbA1c (8.0 ± 0.2% vs. 5.0 ± 0.1%; P < 0.0001), and hs-CRP (1.8 ± 0.3 vs. 0.70 ± 0.2; P = 0.017) than control children without significant differences in BMI, homocysteine, and fibrinogen levels; RBC folate content; and c-IMT between the groups. Children with type 1 diabetes had lower FMD% than control children (7.1 ± 0.8% vs. 9.8 ± 1.1%; P = 0.04), whereas c-IMT did not differ between groups. CONCLUSIONS: Preadolescent children with type 1 diabetes and mean diabetes duration of 4 years displayed evidence of low-intensity vascular inflammation and attenuated FMD measurements. These data suggest that endothelial dysfunction and systemic inflammation, known harbingers of future cardiovascular risk, are present even in preadolescent children.
- 1 February 2011
- Vol. 63 (1) , 35-47
New adolescent polycystic ovary syndrome perspectives.
Polycystic ovary syndrome (PCOS) is a common but heterogeneous disorder that usually arises during puberty. This endocrine disorder is associated with chronic anovulation and hyperandrogenemia with clinical manifestation of oligomenorrhea, hirsutism and acne. While the underlying etiology of PCOS remains unknown, it is commonly associated with obesity and insulin resistance leading to increased risk of cardiovascular disease, dyslipidemia and type 2 diabetes mellitus in hyperandrogenemic phenotypes. Menstrual irregularities and insulin resistance in obese adolescents are usually indistinguishable from the clinical manifestations of PCOS and pose a diagnostic dilemma due to higher circulating androgens during puberty. Consequently, a universal consensus on the definition of hyperandrogenemia in adolescents has been elusive. Nevertheless, hyperandrogenemia, independent of obesity, in postmenarchal adolescents is associated with increased risk of cardiometabolic syndrome. Therefore, treatment strategies including lifestyle changes and/or use of insulin-sensitizers, hormone replacement and antiandrogens should be utilized in order to delay long-term cardiovascular and metabolic complications of this endocrinopathy.
- 1 February 2011
- Vol. 63 (1) , 35-47
New adolescent polycystic ovary syndrome perspectives.
Polycystic ovary syndrome (PCOS) is a common but heterogeneous disorder that usually arises during puberty. This endocrine disorder is associated with chronic anovulation and hyperandrogenemia with clinical manifestation of oligomenorrhea, hirsutism and acne. While the underlying etiology of PCOS remains unknown, it is commonly associated with obesity and insulin resistance leading to increased risk of cardiovascular disease, dyslipidemia and type 2 diabetes mellitus in hyperandrogenemic phenotypes. Menstrual irregularities and insulin resistance in obese adolescents are usually indistinguishable from the clinical manifestations of PCOS and pose a diagnostic dilemma due to higher circulating androgens during puberty. Consequently, a universal consensus on the definition of hyperandrogenemia in adolescents has been elusive. Nevertheless, hyperandrogenemia, independent of obesity, in postmenarchal adolescents is associated with increased risk of cardiometabolic syndrome. Therefore, treatment strategies including lifestyle changes and/or use of insulin-sensitizers, hormone replacement and antiandrogens should be utilized in order to delay long-term cardiovascular and metabolic complications of this endocrinopathy.
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 162 (6) , 1093-1099
Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome
Objective: Polycystic ovary syndrome (PCOS) in adult women is associated with increased risk of metabolic syndrome (MS) and atherosclerosis. We evaluated the spectrum of metabolic dysfunction in relationship with hyperandrogenemia (HA) in adolescent girls with PCOS.Materials and methods: Ovulatory function, acne, hirsutism (HS), body mass index (BMI), body composition, fasting lipids, glucose, insulin, free testosterone (FT), high-sensitivity C-reactive protein (hs-CRP), and HbA1c were evaluated in 103 girls. The homeostatic assessment model equations (HOMA-IR and HOMA-%B) were used for determination of insulin resistance and β-cell function respectively.Results: The oligo-ovulation (Oligo)+HA+HS (n=44), Oligo+HA (n=28), and Oligo+HS (n=31) phenotypes had similar BMI. However, hyperandrogenemic phenotypes had higher prevalence of acanthosis nigricans (AN) and acne (PPr=0.38,Pr=0.49,Pr=0.42,Pr=0.39,Pr=0.27,PP3.0 cut-off values, 71.4% of MS versus 23.5% non-MS group were considered at risk of diabetes and atherosclerosis (P<0.0001).Conclusions: Hyperandrogenemic PCOS phenotypes have greatest degree of insulin resistance and inflammation. The use of insulin resistance and inflammatory markers may help identify adolescent girls with PCOS at risk of cardiometabolic syndrome.
- 1 June 2010
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 162 (6) , 1093-1099
Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome
Objective: Polycystic ovary syndrome (PCOS) in adult women is associated with increased risk of metabolic syndrome (MS) and atherosclerosis. We evaluated the spectrum of metabolic dysfunction in relationship with hyperandrogenemia (HA) in adolescent girls with PCOS.Materials and methods: Ovulatory function, acne, hirsutism (HS), body mass index (BMI), body composition, fasting lipids, glucose, insulin, free testosterone (FT), high-sensitivity C-reactive protein (hs-CRP), and HbA1c were evaluated in 103 girls. The homeostatic assessment model equations (HOMA-IR and HOMA-%B) were used for determination of insulin resistance and β-cell function respectively.Results: The oligo-ovulation (Oligo)+HA+HS (n=44), Oligo+HA (n=28), and Oligo+HS (n=31) phenotypes had similar BMI. However, hyperandrogenemic phenotypes had higher prevalence of acanthosis nigricans (AN) and acne (PPr=0.38,Pr=0.49,Pr=0.42,Pr=0.39,Pr=0.27,PP3.0 cut-off values, 71.4% of MS versus 23.5% non-MS group were considered at risk of diabetes and atherosclerosis (P<0.0001).Conclusions: Hyperandrogenemic PCOS phenotypes have greatest degree of insulin resistance and inflammation. The use of insulin resistance and inflammatory markers may help identify adolescent girls with PCOS at risk of cardiometabolic syndrome.
- 22 September 2009
- Published by Springer Nature in Pituitary
- Vol. 14 (4) , 409-413
Cushing disease as possible cause of persistent growth failure despite growth hormone therapy in a small for gestational age male
Growth hormone (GH) therapy in children with small for gestational age (SGA) has been shown to be of significant therapeutic benefit. We report the case of an 11-year-old Caucasian male who developed early adrenarche, hypertension and insulin resistance on GH therapy for SGA and profound short stature (ht −5 SD). This patient demonstrated a poor response to GH therapy and developed physical and biochemical findings of insulin resistance responsive to metformin therapy. He remained hypertensive, however, and continued to have elevated serum dehydroepiandrosterone sulfate levels. Urinary free cortisol excretion was subsequently found to be elevated. The diagnosis of Cushing’s disease was confirmed with inferior petrosal sinus sampling and pituitary MRI. The patient underwent partial adenohypophysectomy with resulting normalization of plasma cortisol levels and associated symptoms. Our patient’s diagnosis of Cushing’s disease was complicated by his past history of poor growth since birth and history of SGA. The signs of Cushing’s disease did not overtly appear until GH therapy was initiated to help treat severe short stature. It is possible that the metabolic effects of GH therapy unmasked the presence of underlying Cushing’s disease.
- 22 September 2009
- Published by Springer Nature in Pituitary
- Vol. 14 (4) , 409-413
Cushing disease as possible cause of persistent growth failure despite growth hormone therapy in a small for gestational age male
Growth hormone (GH) therapy in children with small for gestational age (SGA) has been shown to be of significant therapeutic benefit. We report the case of an 11-year-old Caucasian male who developed early adrenarche, hypertension and insulin resistance on GH therapy for SGA and profound short stature (ht −5 SD). This patient demonstrated a poor response to GH therapy and developed physical and biochemical findings of insulin resistance responsive to metformin therapy. He remained hypertensive, however, and continued to have elevated serum dehydroepiandrosterone sulfate levels. Urinary free cortisol excretion was subsequently found to be elevated. The diagnosis of Cushing’s disease was confirmed with inferior petrosal sinus sampling and pituitary MRI. The patient underwent partial adenohypophysectomy with resulting normalization of plasma cortisol levels and associated symptoms. Our patient’s diagnosis of Cushing’s disease was complicated by his past history of poor growth since birth and history of SGA. The signs of Cushing’s disease did not overtly appear until GH therapy was initiated to help treat severe short stature. It is possible that the metabolic effects of GH therapy unmasked the presence of underlying Cushing’s disease.
- 1 August 2009
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 11 (8) , 481-486
Feasibility of Continuous Subcutaneous Insulin Infusion and Daily Supplemental Insulin Glargine Injection in Children with Type 1 Diabetes
Background: Continuous subcutaneous insulin infusion (CSII) is an effective method of insulin substitution with increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in rare situations. The lack of subcutaneous long-acting insulin and short half-life of serum insulin increases the risk of ketosis and DKA following CSII failure. We evaluated the metabolic effects of CSII with and without daily supplemental long-acting insulin glargine in a group of young children switched to CSII from multiple daily insulin (premeal aspart + glargine) to either CSII plus daily glargine (CSII + G) or CSII therapy. Methods: From retrospective clinic data, self-monitored blood glucose (SMBG), hemoglobin A1c (HbA 1c ), hypoglycemic episodes, and body mass index (BMI) were obtained from 12 patients (five girls, seven boys; 7.7 ± 1.8 years) on CSII + G and 12 age- and gender-matched patients (five girls, seven boys; 7.7 ± 2.1 years) on CSII with similar baseline HbA 1c and BMI were reviewed over a 1.0-year period. Results: The insulin glargine dose in the CSII + G group was 30.6 ± 12.4% (range, 13.9–53.3%) of daily basal insulin dose. Both groups had similar total daily insulin and bolus:basal insulin at baseline and at 1.0 year. Glycemic control improved in the CSII + G (SMBG, 195.5 ± 47.3 vs. 156.8 ± 36.8 mg/dL, P < 0.05; HbA 1c , 8.1 ± 0.9% vs. 7.4 ± 0.4%, P < 0.02) and CSII (SMBG, 198.7 ± 45.7 vs. 161.4 ± 30.9 mg/dL, P < 0.05; HbA 1c , 8.2 ± 0.4% vs. 7.7 ± 0.5%, P < 0.01) groups without significant changes in hypoglycemic episodes and BMI. There were no DKA episodes despite three emergency room visits for hyperglycemia and ketosis due to catheter dislodgement only in the CSII group. Conclusions: CSII therapy with or without daily insulin glargine improved glycemic control without changes in the rate of hypoglycemia and DKA, suggesting that this treatment regimen is feasible and may also prevent development of hyperglycemia and ketosis or even DKA.
- 1 August 2009
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 11 (8) , 481-486
Feasibility of Continuous Subcutaneous Insulin Infusion and Daily Supplemental Insulin Glargine Injection in Children with Type 1 Diabetes
Background: Continuous subcutaneous insulin infusion (CSII) is an effective method of insulin substitution with increased risk of hypoglycemia and diabetic ketoacidosis (DKA) in rare situations. The lack of subcutaneous long-acting insulin and short half-life of serum insulin increases the risk of ketosis and DKA following CSII failure. We evaluated the metabolic effects of CSII with and without daily supplemental long-acting insulin glargine in a group of young children switched to CSII from multiple daily insulin (premeal aspart + glargine) to either CSII plus daily glargine (CSII + G) or CSII therapy. Methods: From retrospective clinic data, self-monitored blood glucose (SMBG), hemoglobin A1c (HbA 1c ), hypoglycemic episodes, and body mass index (BMI) were obtained from 12 patients (five girls, seven boys; 7.7 ± 1.8 years) on CSII + G and 12 age- and gender-matched patients (five girls, seven boys; 7.7 ± 2.1 years) on CSII with similar baseline HbA 1c and BMI were reviewed over a 1.0-year period. Results: The insulin glargine dose in the CSII + G group was 30.6 ± 12.4% (range, 13.9–53.3%) of daily basal insulin dose. Both groups had similar total daily insulin and bolus:basal insulin at baseline and at 1.0 year. Glycemic control improved in the CSII + G (SMBG, 195.5 ± 47.3 vs. 156.8 ± 36.8 mg/dL, P < 0.05; HbA 1c , 8.1 ± 0.9% vs. 7.4 ± 0.4%, P < 0.02) and CSII (SMBG, 198.7 ± 45.7 vs. 161.4 ± 30.9 mg/dL, P < 0.05; HbA 1c , 8.2 ± 0.4% vs. 7.7 ± 0.5%, P < 0.01) groups without significant changes in hypoglycemic episodes and BMI. There were no DKA episodes despite three emergency room visits for hyperglycemia and ketosis due to catheter dislodgement only in the CSII group. Conclusions: CSII therapy with or without daily insulin glargine improved glycemic control without changes in the rate of hypoglycemia and DKA, suggesting that this treatment regimen is feasible and may also prevent development of hyperglycemia and ketosis or even DKA.
- 30 November 2008
- Published by Elsevier in Metabolism
- Vol. 57 (11) , 1597-1607
Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats
- 30 November 2008
- Published by Elsevier in Metabolism
- Vol. 57 (11) , 1597-1607
Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats
- 19 February 2008
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (6) , 1280-1281
Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft‐versus‐host disease of the liver
We describe a case of extreme hypercholesterolemia, mediated by lipoprotein X, in a 12‐year‐old Caucasian female who underwent an unrelated allogenic bone marrow transplant for relapsed acute myelocytic leukemia (AML). Her post‐transplant course was complicated by severe chronic graft‐versus‐host disease (GVHD) of the liver. Previously normal serum cholesterol and triglycerides rose to 1,122 mg/dl (29.0 mmol/L) and 1,100 mg/dl (12.4 mmol/L), respectively. Serum cholesterol appeared to be dominantly carried by lipoprotein X. Intra‐hepatic cholestasis leading to reflux of bile lipoproteins into the blood stream and subsequent formation of lipoprotein X appears to be the mechanism underlying this phenomenon. Pediatr Blood Cancer 2008;50:1280–1281.
- 19 February 2008
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 50 (6) , 1280-1281
Severe hypercholesterolemia mediated by lipoprotein X in a pediatric patient with chronic graft‐versus‐host disease of the liver
We describe a case of extreme hypercholesterolemia, mediated by lipoprotein X, in a 12‐year‐old Caucasian female who underwent an unrelated allogenic bone marrow transplant for relapsed acute myelocytic leukemia (AML). Her post‐transplant course was complicated by severe chronic graft‐versus‐host disease (GVHD) of the liver. Previously normal serum cholesterol and triglycerides rose to 1,122 mg/dl (29.0 mmol/L) and 1,100 mg/dl (12.4 mmol/L), respectively. Serum cholesterol appeared to be dominantly carried by lipoprotein X. Intra‐hepatic cholestasis leading to reflux of bile lipoproteins into the blood stream and subsequent formation of lipoprotein X appears to be the mechanism underlying this phenomenon. Pediatr Blood Cancer 2008;50:1280–1281.
- 1 February 2008
- Published by Elsevier in Metabolism
- Vol. 57 (2) , 183-191
Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season
- 1 February 2008
- Published by Elsevier in Metabolism
- Vol. 57 (2) , 183-191
Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season
- 1 August 2007
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 9 (4) , 339-347
Continuous Subcutaneous Insulin Infusion Attenuated Glycemic Instability in Preschool Children with Type 1 Diabetes Mellitus
Background/Aims: Continuous subcutaneous insulin infusion (CSII) is believed to decrease glycemic instability and hypoglycemia while increasing quality of life compared to insulin injection regimens. To evaluate indices of glycemic control and impact on quality of life, we studied a group of preschool children with type 1 diabetes mellitus (DM) on CSII. Methods: Fourteen patients (eight girls and six boys) 3.9 ± 0.8 years old with DM duration of 2.0 ± 0.8 years were transitioned from flexible multiple daily insulin (FMDI) (pre-meal aspart and bedtime glargine) to CSII. Patients were evaluated with hemoglobin A1c (HbA1c) and continuous glucose monitoring quarterly for 1 year. Mean blood glucose (MBG), mean amplitude of glycemic excursion (MAGE), and hypoglycemic events (blood glucose 1c (8.0 ± 0.50% vs. 7.8 ± 0.40%) or frequency of hypoglycemia (moderate, 92.3 vs. 73.1 events/100 patient-years; severe, 22.5 vs. 17.5 events/100 patient-years). The MBG (213 ± 94 vs. 185 ± 79 mg/dL) and frequency (1.9 ± 1.6 vs. 2.1 ± 2.2) and duration (nocturnal, 135 ± 141 vs. 120 ± 103 min; total, 267 ± 222 vs. 189 ± 148 min) of hypoglycemic events did not decrease, whereas MAGE was reduced on CSII (210 ± 31 vs. 168 ± 22 mg/dL, P < 0.005). The quality of life subscales on the TAPQoL questionnaire did not change on CSII. Conclusions: CSII improved glycemic instability without reducing HbA1c or frequency and duration of hypoglycemic events and altering the parent's perception of his or her child's quality of life. CSII improves glycemic instability and is an effective alternative to FMDI therapy in young children with type 1 DM.
- 1 August 2007
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 9 (4) , 339-347
Continuous Subcutaneous Insulin Infusion Attenuated Glycemic Instability in Preschool Children with Type 1 Diabetes Mellitus
Background/Aims: Continuous subcutaneous insulin infusion (CSII) is believed to decrease glycemic instability and hypoglycemia while increasing quality of life compared to insulin injection regimens. To evaluate indices of glycemic control and impact on quality of life, we studied a group of preschool children with type 1 diabetes mellitus (DM) on CSII. Methods: Fourteen patients (eight girls and six boys) 3.9 ± 0.8 years old with DM duration of 2.0 ± 0.8 years were transitioned from flexible multiple daily insulin (FMDI) (pre-meal aspart and bedtime glargine) to CSII. Patients were evaluated with hemoglobin A1c (HbA1c) and continuous glucose monitoring quarterly for 1 year. Mean blood glucose (MBG), mean amplitude of glycemic excursion (MAGE), and hypoglycemic events (blood glucose 1c (8.0 ± 0.50% vs. 7.8 ± 0.40%) or frequency of hypoglycemia (moderate, 92.3 vs. 73.1 events/100 patient-years; severe, 22.5 vs. 17.5 events/100 patient-years). The MBG (213 ± 94 vs. 185 ± 79 mg/dL) and frequency (1.9 ± 1.6 vs. 2.1 ± 2.2) and duration (nocturnal, 135 ± 141 vs. 120 ± 103 min; total, 267 ± 222 vs. 189 ± 148 min) of hypoglycemic events did not decrease, whereas MAGE was reduced on CSII (210 ± 31 vs. 168 ± 22 mg/dL, P < 0.005). The quality of life subscales on the TAPQoL questionnaire did not change on CSII. Conclusions: CSII improved glycemic instability without reducing HbA1c or frequency and duration of hypoglycemic events and altering the parent's perception of his or her child's quality of life. CSII improves glycemic instability and is an effective alternative to FMDI therapy in young children with type 1 DM.
- 1 January 2006
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 19 (9) , 1141-1150
Predictors of Metabolic Control at One Year in a Population of Pediatric Patients with Type 2 Diabetes Melttus: A Retrospective Study
The rising prevalence of pediatric type 2 diabetes mellitus (DM2) and non-adherence to diabetes regimens pose challenges to obtaining optimal control. This study evaluated factors that may impact glycemic control (HbA1c): age, Tanner stage, body mass index (BMI), total daily insulin (TDD), metformin dose (MET), activity level, frequency of clinic visits and adherence. One-year data from 72 patients (ages 8.6-17.8 years) were collected retrospectively. From that sample, 57 patients who continued to attend clinic for the entire year were assessed and divided into optimal and suboptimal HbA1c control groups. All factors measured were similar in the two groups, except for lower initial and 1.0-year HbA1c, TDD, and rates of missing MET and insulin in the optimal HbA1c control group. Initial glycemic status and adherence rate predicted metabolic control at one year. Early identification of DM2 may improve metabolic outcome, which may improve medical regimen adherence.
- 1 January 2006
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 19 (9) , 1141-1150
Predictors of Metabolic Control at One Year in a Population of Pediatric Patients with Type 2 Diabetes Melttus: A Retrospective Study
The rising prevalence of pediatric type 2 diabetes mellitus (DM2) and non-adherence to diabetes regimens pose challenges to obtaining optimal control. This study evaluated factors that may impact glycemic control (HbA1c): age, Tanner stage, body mass index (BMI), total daily insulin (TDD), metformin dose (MET), activity level, frequency of clinic visits and adherence. One-year data from 72 patients (ages 8.6-17.8 years) were collected retrospectively. From that sample, 57 patients who continued to attend clinic for the entire year were assessed and divided into optimal and suboptimal HbA1c control groups. All factors measured were similar in the two groups, except for lower initial and 1.0-year HbA1c, TDD, and rates of missing MET and insulin in the optimal HbA1c control group. Initial glycemic status and adherence rate predicted metabolic control at one year. Early identification of DM2 may improve metabolic outcome, which may improve medical regimen adherence.